Basic studies on the clinical applications of platelet-rich plasma

Masaki Yazawa, Hisao Ogata, Tatsuo Nakajima, Taisuke Mori, Naohide Watanabe, Makoto Handa

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Platelets, which contain many growth factors such as platelet-derived growth factor (PDGF) and transforming growth factor-β (TGF-β), are being used in clinical applications as platelet-rich plasma (PRP). Only a few studies, however, have been conducted on the growth factors present in PRP and on the clinical applications using the drug delivery system (DDS). For the purpose of clinical application, we first modified the PRP preparation method and assessed the amounts of growth factors contained in the human platelet concentrates. Furthermore, we assessed fibrin glue as a DDS of platelet concentrates. Platelet precipitations were made by twice centrifuging human whole blood. The precipitated platelet was resuspended to yield the platelet concentrates. The growth factor concentrations were measured. Fibrin glue sheets containing this platelet concentrate were implanted in rabbit pinna and samples were obtained for immunostaining (anti-PDGF antibody) to assess the use of PRP over time using the fibrin glue as the DDS. The mean concentration of growth factors present in the platelet concentrates was three times or greater than that of conventional PRP. Furthermore, the results indicated that when the platelet concentrate was used with fibrin glue as a carrier, the contents were released over a period of about 1 week. This raises the possibility that this system may be useful in clinical applications.

Original languageEnglish
Pages (from-to)509-518
Number of pages10
JournalCell Transplantation
Volume12
Issue number5
Publication statusPublished - 2003

Fingerprint

Platelet-Rich Plasma
Platelets
Blood Platelets
Plasmas
Fibrin Tissue Adhesive
Intercellular Signaling Peptides and Proteins
Drug Delivery Systems
Glues
Platelet-Derived Growth Factor
Clinical Studies
Transforming Growth Factors
Rabbits
Antibodies

Keywords

  • Drug delivery system
  • Fibrin glue
  • Platelet-rich plasma
  • Platlet-derived growth factor

ASJC Scopus subject areas

  • Cell Biology
  • Transplantation

Cite this

Yazawa, M., Ogata, H., Nakajima, T., Mori, T., Watanabe, N., & Handa, M. (2003). Basic studies on the clinical applications of platelet-rich plasma. Cell Transplantation, 12(5), 509-518.

Basic studies on the clinical applications of platelet-rich plasma. / Yazawa, Masaki; Ogata, Hisao; Nakajima, Tatsuo; Mori, Taisuke; Watanabe, Naohide; Handa, Makoto.

In: Cell Transplantation, Vol. 12, No. 5, 2003, p. 509-518.

Research output: Contribution to journalArticle

Yazawa, M, Ogata, H, Nakajima, T, Mori, T, Watanabe, N & Handa, M 2003, 'Basic studies on the clinical applications of platelet-rich plasma', Cell Transplantation, vol. 12, no. 5, pp. 509-518.
Yazawa M, Ogata H, Nakajima T, Mori T, Watanabe N, Handa M. Basic studies on the clinical applications of platelet-rich plasma. Cell Transplantation. 2003;12(5):509-518.
Yazawa, Masaki ; Ogata, Hisao ; Nakajima, Tatsuo ; Mori, Taisuke ; Watanabe, Naohide ; Handa, Makoto. / Basic studies on the clinical applications of platelet-rich plasma. In: Cell Transplantation. 2003 ; Vol. 12, No. 5. pp. 509-518.
@article{575fc919b11e48d39e9f87371bf46ade,
title = "Basic studies on the clinical applications of platelet-rich plasma",
abstract = "Platelets, which contain many growth factors such as platelet-derived growth factor (PDGF) and transforming growth factor-β (TGF-β), are being used in clinical applications as platelet-rich plasma (PRP). Only a few studies, however, have been conducted on the growth factors present in PRP and on the clinical applications using the drug delivery system (DDS). For the purpose of clinical application, we first modified the PRP preparation method and assessed the amounts of growth factors contained in the human platelet concentrates. Furthermore, we assessed fibrin glue as a DDS of platelet concentrates. Platelet precipitations were made by twice centrifuging human whole blood. The precipitated platelet was resuspended to yield the platelet concentrates. The growth factor concentrations were measured. Fibrin glue sheets containing this platelet concentrate were implanted in rabbit pinna and samples were obtained for immunostaining (anti-PDGF antibody) to assess the use of PRP over time using the fibrin glue as the DDS. The mean concentration of growth factors present in the platelet concentrates was three times or greater than that of conventional PRP. Furthermore, the results indicated that when the platelet concentrate was used with fibrin glue as a carrier, the contents were released over a period of about 1 week. This raises the possibility that this system may be useful in clinical applications.",
keywords = "Drug delivery system, Fibrin glue, Platelet-rich plasma, Platlet-derived growth factor",
author = "Masaki Yazawa and Hisao Ogata and Tatsuo Nakajima and Taisuke Mori and Naohide Watanabe and Makoto Handa",
year = "2003",
language = "English",
volume = "12",
pages = "509--518",
journal = "Cell Transplantation",
issn = "0963-6897",
publisher = "Cognizant Communication Corporation",
number = "5",

}

TY - JOUR

T1 - Basic studies on the clinical applications of platelet-rich plasma

AU - Yazawa, Masaki

AU - Ogata, Hisao

AU - Nakajima, Tatsuo

AU - Mori, Taisuke

AU - Watanabe, Naohide

AU - Handa, Makoto

PY - 2003

Y1 - 2003

N2 - Platelets, which contain many growth factors such as platelet-derived growth factor (PDGF) and transforming growth factor-β (TGF-β), are being used in clinical applications as platelet-rich plasma (PRP). Only a few studies, however, have been conducted on the growth factors present in PRP and on the clinical applications using the drug delivery system (DDS). For the purpose of clinical application, we first modified the PRP preparation method and assessed the amounts of growth factors contained in the human platelet concentrates. Furthermore, we assessed fibrin glue as a DDS of platelet concentrates. Platelet precipitations were made by twice centrifuging human whole blood. The precipitated platelet was resuspended to yield the platelet concentrates. The growth factor concentrations were measured. Fibrin glue sheets containing this platelet concentrate were implanted in rabbit pinna and samples were obtained for immunostaining (anti-PDGF antibody) to assess the use of PRP over time using the fibrin glue as the DDS. The mean concentration of growth factors present in the platelet concentrates was three times or greater than that of conventional PRP. Furthermore, the results indicated that when the platelet concentrate was used with fibrin glue as a carrier, the contents were released over a period of about 1 week. This raises the possibility that this system may be useful in clinical applications.

AB - Platelets, which contain many growth factors such as platelet-derived growth factor (PDGF) and transforming growth factor-β (TGF-β), are being used in clinical applications as platelet-rich plasma (PRP). Only a few studies, however, have been conducted on the growth factors present in PRP and on the clinical applications using the drug delivery system (DDS). For the purpose of clinical application, we first modified the PRP preparation method and assessed the amounts of growth factors contained in the human platelet concentrates. Furthermore, we assessed fibrin glue as a DDS of platelet concentrates. Platelet precipitations were made by twice centrifuging human whole blood. The precipitated platelet was resuspended to yield the platelet concentrates. The growth factor concentrations were measured. Fibrin glue sheets containing this platelet concentrate were implanted in rabbit pinna and samples were obtained for immunostaining (anti-PDGF antibody) to assess the use of PRP over time using the fibrin glue as the DDS. The mean concentration of growth factors present in the platelet concentrates was three times or greater than that of conventional PRP. Furthermore, the results indicated that when the platelet concentrate was used with fibrin glue as a carrier, the contents were released over a period of about 1 week. This raises the possibility that this system may be useful in clinical applications.

KW - Drug delivery system

KW - Fibrin glue

KW - Platelet-rich plasma

KW - Platlet-derived growth factor

UR - http://www.scopus.com/inward/record.url?scp=0042664179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042664179&partnerID=8YFLogxK

M3 - Article

C2 - 12953925

AN - SCOPUS:0042664179

VL - 12

SP - 509

EP - 518

JO - Cell Transplantation

JF - Cell Transplantation

SN - 0963-6897

IS - 5

ER -